Table 3 Major results from the HER2-scores analyses (n=47)
HER2-scores characteristics | Fraction | Percentage |
|---|---|---|
Primary tumours with 3+ | 23/47 | 49 |
Primary tumours with 2+ or 3+ | 26/47 | 55 |
Lymph node metastases with 3+ | 22/47 | 47 |
Lymph node metastases with 2+ or 3+ | 26/47 | 55 |
Unchanged HER2-scores in lymph node metastases vs the primary tumour | 40/47 | 85 |
Changed HER2-scores in lymph node metastases vs the primary tumour | 7/47 | 15 |
Patients who had 0 or 1+ in primary tumours and changed to 2+ or 3+ in lymph node metastases | 0/47 | 0 |
Patients who had 2+ or 3+ in primary tumours and changed to 0 or 1+ in lymph node metastases | 0/47 | 0 |
